The effect of chemo-immunotherapy with SDDS, pyrimethamine and anti-toxoplasma serum on toxoplasma gondii cysts in latent infected NMRI mice.
A substantial reduction of brain cyst numbers could be obtained through a six week therapy with SDDS-pyrimethamine combination or a high titer anti-Toxoplasma serum. NMRI mice experimentally infected three months earlier with cyst-forming Toxoplasma strains Witting, Alt or Gail were used. The effectiveness of the treatments could be increased considerably by simultaneous administration of anti-Toxoplasma serum and SDDS-pyrimethamine. A highly significant reduction of brain cyst numbers, upto 65%, could be obtained by using this mode of chemoimmunotherapy. The effectiveness of the treatments used varied amongst the three Toxoplasma strains.
D000818:Animals; D001927:Brain Diseases / Q000188:drug therapy / Q000628:therapy*; D003560:Cysts / Q000188:drug therapy / Q000628:therapy*; D003622:Dapsone / Q000031:analogs & derivatives; D005260:Female; D007167:Immunotherapy; D051379:Mice; D008815:Mice, Inbred Strains; D011739:Pyrimethamine / Q000627:therapeutic use*; D013415:Sulfalene / Q000627:therapeutic use; D013424:Sulfanilamides / Q000627:therapeutic use*; D013450:Sulfones / Q000627:therapeutic use; D014124:Toxoplasmosis, Animal / Q000188:drug therapy / Q000628:therapy*
D013424:Sulfanilamides; D013450:Sulfones; C003361:SDDS; D003622:Dapsone; D013415:Sulfalene; D011739:Pyrimethamine